Medicus Pharma Ltd 2025年季度报告

FORM10-Q (MARK ONE) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 MEDICUS PHARMA LTD. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2of the Exchange Act). As of May 8, 2025, there were13,494,861common shares, no par value, issued and outstanding. Part I.Financial Information CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this QuarterlyReport on Form 10-Q regarding our strategy, future operations, future financial position, projected costs, prospects, plans, andobjectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties, andother important factors that may cause our actual results, performance, or achievements to be materially different from any futureresults, performance, or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," The forward-looking statements in this Quarterly Report on Form 10-Q and those contained in (i) our Annual Report on Form 10-Kfiled with the United States Securities and Exchange Commission ("SEC") on March 28, 2025 (the "2024 Annual Report") include, our financial results, including our ability to generate earnings and achieve and sustain profitability, which may varysignificantly from forecasts and from period to period; the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products andproduct candidates; our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates; our ability to develop, manage and maintain our direct sales and marketing organizations; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additionalfinancing; market risks regarding consolidation in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third partypayors for procedures using our products significantly declines; our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectualproperty rights of others; the fact that product quality issues or product defects may harm our business; any product liability claims; and the regulatory, legal and certain operating risks that our operations subject us to. The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefsconcerning future developments and their potential effects on us. There can be no assurance that future developments affecting us willbe those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which arebeyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressedor implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors describedunder the heading "Risk Factors" in Part I, Item 1A in the 2024 Annual Report and Part II, Item 1A of this Quarterly Report on Form 1. Description of business Medicus Pharma Ltd. (the "Company" or "Medicus Pharma"), formerly Interactive Capital Partners Corporation ("Interactive"), is aclinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology The